Top

Clinical and Translational Oncology

Published in:

01-11-2016 | Research Article

Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1α/VEGF signals

Authors: Y. Zhao, W. You, J. Zheng, Y. Chi, W. Tang, R. Du

Published in: Clinical and Translational Oncology | Issue 11/2016

Abstract

Purpose

Cervical cancer is one of the most prevalent malignancies in women worldwide. Therefore, the investigation about the molecular pathogenesis and related therapy targets of cervical cancer is an emergency. The objective of the present study is to investigate the effects of valproic acid (VPA), a histone deacetylase inhibitor, on the angiogenesis of cervical cancer.

Methods

The effects and mechanisms of VPA on in vitro angiogenesis and vascular endothelial growth factor (VEGF) expression of human cervical cancer HeLa and SiHa cells were investigated.

Results

Our present study reveals that 1 mM VPA can significantly inhibit the in vitro angiogenic potential and VEGF expression of human cervical cancer HeLa and SiHa cells. Further, the transcription and protein levels of hypoxia inducible factor-1α (HIF-1α), and not HIF-1β, are significantly inhibited in VPA-treated cervical cancer cells. Over expression of HIF-1α can obviously reverse VPA-induced VEGF down regulation. VPA-treatment decreases the activation of Akt and ERK1/2 in both HeLa and SiHa cells in a time-dependent manner. The inhibitor of Akt (LY 294002) or ERK1/2 (PD98059) can inhibit VEGF alone and cooperatively reinforce the suppression effects of VPA on HIF-1α and VEGF expression.

Conclusion

Collectively, our data reveal that the inhibition of PI3K/Akt and ERK1/2 signals are involved in VPA-induced HIF-1α and VEGF suppression of cervical cancer cells.

Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675–86.CrossRefPubMed

Maestri D, Reis RJ, Bacha OM, Muller B, Corleta OC. A comparison of radical vaginal hysterectomy combined with extraperitoneal or laparoscopic pelvic lymphadenectomy in the treatment of cervical cancer. Int J Gynecol Cancer. 2012;22:1238–43.PubMed

Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.CrossRefPubMedPubMedCentral

Baylin SB, Jones PA. A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer. 2011;11:726–34.CrossRefPubMedPubMedCentral

Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci. 2014;71:3885–901.CrossRefPubMedPubMedCentral

van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256:1519–26.CrossRefPubMed

Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969–78.CrossRefPubMedPubMedCentral

Liu X, Chen L, Sun F, Zhang G. Enhanced suppression of proliferation and migration in highly-metastatic lung cancer cells by combination of valproic acid and coumarin-3-carboxylic acid and its molecular mechanisms of action. Cytotechnology. 2013;65:597–608.CrossRefPubMed

Yang FQ, Liu M, Yang FP, Che J, Li W, Zhai W, et al. VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1alpha. Mol Biol Rep. 2014;41:1511–8.CrossRefPubMed

10.

Wang D, Jing Y, Ouyang S, Liu B, Zhu T, Niu H, et al. Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo. Oncol Lett. 2013;6:1492–8.PubMedPubMedCentral

11.

Moreaux J, Reme T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer. 2013;109:676–85.CrossRefPubMedPubMedCentral

12.

Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009;280:145–53.CrossRefPubMed

13.

Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67:5064–6.CrossRefPubMed

14.

Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002;21:427–36.CrossRefPubMed

15.

Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer. 2002;97:290–6.CrossRefPubMed

16.

Shan Z, Feng-Nian R, Jie G, Ting Z. Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo. Asian Pac J Cancer Prev. 2012;13:3977–82.CrossRefPubMed

17.

Osuka S, Takano S, Yamamoto T, Ishikawa E, Matsumura A. Histone deacetylase inhibitor, valproic acid inhibits glioma angiogenesis in vitro and in vivo in the brain. Neuro-oncol. 2009;11:962.

18.

Zhang ZH, Hao CL, Liu P, Tian X, Wang LH, Zhao L, et al. Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi1 leukemia cells. Mol Med Rep. 2013;9:443–9.PubMedPubMedCentral

19.

Ge LC, Chen ZJ, Liu HY, Zhang KS, Liu H, Huang HB, et al. Involvement of activating ERK1/2 through G protein coupled receptor 30 and estrogen receptor alpha/beta in low doses of bisphenol A promoting growth of Sertoli TM4 cells. Toxicol Lett. 2014;226:81–9.CrossRefPubMed

20.

Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 2005;19:342–53.CrossRefPubMed

21.

Mawatari T, Ninomiya I, Inokuchi M, Harada S, Hayashi H, Oyama K, et al. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. Int J Oncol. 2015;47:2073–81.PubMedPubMedCentral

22.

Sami S, Hoti N, Xu HM, Shen ZL, Huang XF. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem (Tokyo). 2008;144:357–62.CrossRef

23.

Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–13.CrossRefPubMedPubMedCentral

24.

Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 1996;271:17771–8.CrossRefPubMed

25.

Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res. 2001;61:7349–55.PubMed

26.

Shen K, Ji L, Gong C, Ma Y, Yang L, Fan Y, et al. Notoginsenoside Ft1 promotes angiogenesis via HIF-1alpha mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Biochem Pharmacol. 2012;84:784–92.CrossRefPubMed

27.

Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE, et al. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol. 2007;85:159–70.CrossRefPubMed

28.

Byler TK, Leocadio D, Shapiro O, Bratslavsky G, Stodgell CJ, Wood RW, et al. Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. BMC Urol. 2012;12:21.CrossRefPubMedPubMedCentral

29.

Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302–8.CrossRefPubMed

30.

Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol. 2004;65:520–7.CrossRefPubMed

31.

Isenberg JS, Jia Y, Field L, Ridnour LA, Sparatore A, Del Soldato P, et al. Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol. 2007;151:63–72.CrossRefPubMed

32.

Zgouras D, Becker U, Loitsch S, Stein J. Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun. 2004;316:693–7.CrossRefPubMed

33.

Gao D, Xia Q, Lv J, Zhang H. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo. Int J Urol. 2007;14:838–45.CrossRefPubMed

34.

Kitazoe K, Abe M, Hiasa M, Oda A, Amou H, Harada T, et al. Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. Int J Hematol. 2009;89:45–57.CrossRefPubMed

35.

Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001;7:437–43.CrossRefPubMed

36.

Luo HM, Du MH, Lin ZL, Zhang L, Ma L, Wang H, et al. Valproic acid treatment inhibits hypoxia-inducible factor 1alpha accumulation and protects against burn-induced gut barrier dysfunction in a rodent model. PLoS One. 2013;8:e77523.CrossRefPubMedPubMedCentral

37.

Chen SY, Sang NL. Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol. 2011;2011:197946.PubMed

38.

Wang JH, Wang JC, Sun YX, Song WY, Nor JE, Wang CY, et al. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal. 2005;17:1578–92.CrossRefPubMed

39.

Zhou CL, Yu XJ, Chen LM, Jiang H, Li CY. Corticotropin-releasing hormone attenuates vascular endothelial growth factor release from human HaCaT keratinocytes. Regul Pept. 2010;160:115–20.CrossRefPubMed

Title: Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1α/VEGF signals
Authors: Y. Zhao
W. You
J. Zheng
Y. Chi
W. Tang
R. Du
Publication date: 01-11-2016
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 11/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-016-1494-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2016

Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II–III esophageal carcinoma

Survival in glioblastoma: a review on the impact of treatment modalities

Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer

Regulation of epithelial–mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs

Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location

Extreme liver surgery as treatment of liver tumors involving the hepatocaval confluence

Keynote webinar | Spotlight on antibody–drug conjugates in cancer